Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Mulligan

Showing results (511-520 of 529) with videos related to

Pageof 53
Sort By:
JAMA|June 3, 2021
Effect of Bamlanivimab vs Placebo on Incidence of COVID-19 Among Residents and Staff of Skilled Nursing and Assisted Living Facilities: A Randomized Clinical TrialMyron S Cohen, Ajay Nirula, Mark J Mulligan, et al.
NPJ Vaccines|March 30, 2024
Heterologous cAd3-Ebola and MVA-EbolaZ vaccines are safe and immunogenic in US and Uganda phase 1/1b trialsMyra Happe, Amelia R Hofstetter, Jing Wang, et al.
The Journal of Infectious Diseases|April 29, 2025
Mucosal and Systemic Antibody Responses After Boosting With a Bivalent Messenger RNA Severe Acute Respiratory Syndrome Coronavirus 2 VaccineRobert L Atmar, Kirsten E Lyke, Christine M Posavad, et al.
Physical Review Letters|July 2, 2021
Phenomenological Constraints on the Transport Properties of QCD Matter with Data-Driven Model AveragingD Everett, W Ke, J-F Paquet, et al.
Medrxiv : the Preprint Server for Health Sciences|October 21, 2021
Heterologous SARS-CoV-2 Booster Vaccinations - Preliminary ReportRobert L Atmar, Kirsten E Lyke, Meagan E Deming, et al.
The New England Journal of Medicine|January 26, 2022
Homologous and Heterologous Covid-19 Booster VaccinationsRobert L Atmar, Kirsten E Lyke, Meagan E Deming, et al.
Cell Reports. Medicine|July 7, 2022
Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variantKirsten E Lyke, Robert L Atmar, Clara Dominguez Islas, et al.
Genome Research|October 23, 2020
Sequencing identifies multiple early introductions of SARS-CoV-2 to the New York City regionMatthew T Maurano, Sitharam Ramaswami, Paul Zappile, et al.
The New England Journal of Medicine|September 29, 2021
Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 VaccineAnn R Falsey, Magdalena E Sobieszczyk, Ian Hirsch, et al.
Medrxiv : the Preprint Server for Health Sciences|June 9, 2020
Sequencing identifies multiple early introductions of SARS-CoV-2 to the New York City RegionMatthew T Maurano, Sitharam Ramaswami, Paul Zappile, et al.
Pageof 53

Showing results (511-520 of 529) with videos related to

Sort By:
Pageof 53
JAMA|June 3, 2021
Effect of Bamlanivimab vs Placebo on Incidence of COVID-19 Among Residents and Staff of Skilled Nursing and Assisted Living Facilities: A Randomized Clinical TrialMyron S Cohen, Ajay Nirula, Mark J Mulligan, et al.
NPJ Vaccines|March 30, 2024
Heterologous cAd3-Ebola and MVA-EbolaZ vaccines are safe and immunogenic in US and Uganda phase 1/1b trialsMyra Happe, Amelia R Hofstetter, Jing Wang, et al.
The Journal of Infectious Diseases|April 29, 2025
Mucosal and Systemic Antibody Responses After Boosting With a Bivalent Messenger RNA Severe Acute Respiratory Syndrome Coronavirus 2 VaccineRobert L Atmar, Kirsten E Lyke, Christine M Posavad, et al.
Physical Review Letters|July 2, 2021
Phenomenological Constraints on the Transport Properties of QCD Matter with Data-Driven Model AveragingD Everett, W Ke, J-F Paquet, et al.
Medrxiv : the Preprint Server for Health Sciences|October 21, 2021
Heterologous SARS-CoV-2 Booster Vaccinations - Preliminary ReportRobert L Atmar, Kirsten E Lyke, Meagan E Deming, et al.
The New England Journal of Medicine|January 26, 2022
Homologous and Heterologous Covid-19 Booster VaccinationsRobert L Atmar, Kirsten E Lyke, Meagan E Deming, et al.
Cell Reports. Medicine|July 7, 2022
Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variantKirsten E Lyke, Robert L Atmar, Clara Dominguez Islas, et al.
Genome Research|October 23, 2020
Sequencing identifies multiple early introductions of SARS-CoV-2 to the New York City regionMatthew T Maurano, Sitharam Ramaswami, Paul Zappile, et al.
The New England Journal of Medicine|September 29, 2021
Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 VaccineAnn R Falsey, Magdalena E Sobieszczyk, Ian Hirsch, et al.
Medrxiv : the Preprint Server for Health Sciences|June 9, 2020
Sequencing identifies multiple early introductions of SARS-CoV-2 to the New York City RegionMatthew T Maurano, Sitharam Ramaswami, Paul Zappile, et al.
Pageof 53